newsfilter
← Latest News
GlobeNewswire·

Ovid Therapeutics Reports Business Updates and Fourth Quarter and Full Year 2024 Financial Results

Stelios Papadopolous, Ph.D., a pioneering leader in biotech, appointed to Board of Directors; two industry veterans joined management team as Ovid prepares to take OV329 into patient trials and move its first KCC2 direct